Open AccessBeyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent β-Lactam−β-Lactamase Inhibitor Combination
Author(s) -
Krisztina M. PappWallace,
Christopher R. Bethel,
J. Caillon,
Melissa D. Barnes,
G. Potel,
Saralee Bajaksouzian,
Joseph Rutter,
Amokrane Reghal,
Stuart Shapiro,
Magdalena A. Taracila,
Michael R. Jacobs,
Robert A. Bonomo,
Cédric Jacqueline
Publication year - 2019
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00105-19
Subject(s) - cefepime , tazobactam , piperacillin , piperacillin/tazobactam , microbiology and biotechnology , antibiotics , antimicrobial , cephalosporin , beta lactamase inhibitors , pharmacology , biology , antibiotic resistance , medicine , bacteria , imipenem , pseudomonas aeruginosa , genetics
Impeding, as well as reducing, the burden of antimicrobial resistance in Gram-negative pathogens is an urgent public health endeavor. Our current antibiotic armamentarium is dwindling, while major resistance determinants (e.g., extended-spectrum β-lactamases [ESBLs]) continue to evolve and disseminate around the world.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom